Get the Daily Brief
Latest Biotech News
Senate passes Biosecure Act as NDAA amendment — supply chain rules shift
The U.S. Senate approved a new iteration of the Biosecure Act as an amendment to the National Defense Authorization Act for FY2026. The revised bill seeks to restrict federal funding or...
Pan‑disease blood proteome map...a 9K‑sample resource for biomarkers
An international consortium led by SciLifeLab and KTH published a large‑scale proteomic atlas profiling ~9,000 blood samples across 59 diseases using Olink Explore/Explore HT platforms and made...
Epigenetic editing cuts PCSK9, slashes LDL in primates
Researchers delivered an mRNA‑based epigenetic editor targeting PCSK9 to nonhuman primate livers and reported durable reductions in PCSK9 expression and LDL cholesterol for nearly a year after a...
Illumina’s genomic alliance draws pharma partners — target discovery ramp
Illumina expanded its Alliance for Genomic Discovery partnerships, adding Alnylam Pharmaceuticals and attracting pharma interest in large, linked genomic‑clinical datasets from biobanks such as...
Altos Labs tests anti‑aging biology in perfused organs — ex vivo platform advances
Altos Labs disclosed work testing rejuvenation therapies in organs maintained ex vivo, advancing its program to evaluate anti‑aging interventions outside the body. The company is reportedly using...
Head of FDA orphan drug office reassigned — orphan pathways face scrutiny
The director of the FDA Office that oversees orphan drug designations was removed from the role and reassigned, an administrative official confirmed. Sandra Retzky’s reassignment affects the...
BMS buys Orbital for $1.5B: in vivo CAR‑T push
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in cash to add in vivo CAR‑T capabilities to its pipeline. The deal brings Orbital’s lead program, OTX‑201, and its...
Novo buys Akero — shutters cell therapy unit: strategy pivot
Novo Nordisk announced the acquisition of Akero Therapeutics for $4.7 billion to secure efruxifermin, an FGF21 analogue in late‑stage development for metabolic dysfunction‑associated...
Gene editing bets deepen: Mammoth trial planned — epigenetic PCSK9 edit shows durable LDL cuts
Mammoth Biosciences disclosed preclinical primate data for its lead gene‑editing program and signaled plans to move toward first‑in‑human testing of a triglyceride‑lowering editing approach, while...
Part of pig liver transplanted into human…functioned for 38 days
Chinese surgeons transplanted a genetically modified pig liver segment into a patient with an inoperable tumor and reported the graft supported metabolic functions for 38 days before removal, with...
Sarepta to file for LGMD gene therapy: first treatment in rare disease class
Sarepta Therapeutics presented data showing its experimental gene therapy increased expression of the missing gene in limb girdle muscular dystrophy 2E (LGMD2E) and said it plans to file for...
FDA orphan drug office chief reassigned: internal leadership shift
The director of the FDA office that oversees orphan drug designations was removed from the role and reassigned, an administration official confirmed to Endpoints News. Sandra Retzky’s reassignment...
Senate passes Biosecure Act — new limits on certain biotech ties
The U.S. Senate passed a revised Biosecure Act as an amendment to the National Defense Authorization Act, authorizing restrictions on federal funding or contracting with designated 'biotechnology...
Red team exposes gaps in DNA screening: AI‑designed proteins evade sequence checks
A Microsoft‑led red‑team exercise demonstrated that structure‑preserving, AI‑designed protein sequences can evade traditional sequence‑based nucleic acid screening tools, prompting recommendations...
Illumina’s alliance draws pharma: 250K genomes, pharma partners seek targets
Illumina’s Alliance for Genomic Discovery expanded its roster of industry partners—adding Alnylam Pharmaceuticals among others—and now includes more than 250,000 sequenced genomes from...
Evommune files IPO: raise to fund two Phase‑2 immune drugs
Evommune filed to go public to finance late‑stage development of two mid‑stage candidates targeting chronic inflammatory conditions: EVO756, an oral MRGPRX2 antagonist for chronic spontaneous...
BMS bets on in vivo CAR‑T: $1.5B Orbital buy
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in cash, folding the three‑year‑old startup’s in vivo CAR‑T platform into its cell‑therapy pipeline. The deal,...
Novo doubles down on MASH — $4.7B Akero takeover
Novo Nordisk agreed to acquire Akero Therapeutics for $4.7 billion upfront to secure efruxifermin, an FGF21 analogue in phase 3 for metabolic dysfunction‑associated steatohepatitis (MASH)....
Senate passes Biosecure Act: NDAA embeds new biotech limits
The US Senate inserted a revised Biosecure Act into the National Defense Authorization Act, voting to restrict federal funding and contracting with biotechnology companies deemed a national...
Mammoth pushes gene edit trial — anti‑AAV immunity still a hurdle
Mammoth Biosciences announced plans to advance its triglyceride‑lowering gene‑editing program into first‑in‑human testing, revealing nonhuman primate data and plans for an early trial. The company...